GlassScriptPhysician profile
Ramon C Sanchez
NPI 1861572125
$13,624.59
in general payments reported to CMS, 2019-2025
47 companies · $3,598 in 2025
The $3,598 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $946 · 2020: $328 · 2021: $1,137 · 2022: $1,590 · 2023: $2,728 · 2024: $3,298 · 2025: $3,598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,586 · Education: $36.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,586.40 |
| Education | $36.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,322.79 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $1,450.02 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $1,340.35 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Novo Nordisk INC | $778.00 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Axsome Therapeutics, INC. | $773.79 | 2022-2025 | Auvelity |
| Amgen INC. | $761.74 | 2019-2025 | Repatha, Repatha |
| Tris Pharma INC | $587.06 | 2023-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Supernus Pharmaceuticals, INC. | $521.57 | 2021-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $469.77 | 2024-2025 | Fanapt |
| Lundbeck LLC | $440.81 | 2020-2025 | Rexulti |
| Jazz Pharmaceuticals INC. | $433.83 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $335.71 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $313.01 | 2021-2024 | |
| Allergan, INC. | $263.66 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $251.67 | 2024-2025 | Caplyta |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramon Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.